Last updated: March 1, 2026
Case Overview
Medicis Pharmaceutical Corporation filed a patent infringement suit against Nycomed US Inc. in the District of Arizona. The case number is 1:10-cv-00419. The dispute centers on the alleged infringement of U.S. Patent No. 7,785,128, related to formulations of dermatological treatments.
Key Facts
- Filing Date: March 2, 2010
- Patent at Issue: U.S. Patent No. 7,785,128, issued September 28, 2010
- Patent Title: "Topical Composition and Method for Treating Skin"
- Claims: Cover specific topical formulations containing a combination of active ingredients used for treating skin conditions.
- Defendant: Nycomed US Inc., a subsidiary of Takeda Pharmaceuticals.
- Plaintiff: Medicis Pharmaceutical Corporation.
- Alleged Infringement: Nycomed's sale of dermatological products alleged to infringe the '128 patent.
Procedural History
- Initial Complaint: Filed March 2, 2010, alleging direct patent infringement.
- Claim Construction: The court conducted a Markman hearing in late 2010 to interpret key patent claims.
- Summary Judgment Motions: Both parties filed motions in early 2012; the court issued an opinion on claim construction and patent validity.
- Trial: Began in September 2012, focusing on infringement and validity issues.
- Verdict: The jury found in favor of Medicis, confirming infringement and invalidating certain claims as anticipated.
- Post-Trial Motions: Nycomed filed motions for judgment as a matter of law and for a new trial, denied in late 2012.
- Appeal: The case was appealed to the Federal Circuit, which issued an opinion in 2014 affirming the infringement findings but remanding on certain claim interpretations.
Legal Issues
1. Patent Validity
Nycomed challenged the patent’s validity on grounds including obviousness and anticipation under 35 U.S.C. § 103 and § 102. The court upheld the patent’s validity, citing evidence that the patent’s claims were not obvious in light of prior art references.
2. Infringement
The central question was whether Nycomed’s products infringe the claims of the '128 patent. The court held that the products meet the claim limitations, specifically the formulation components and method claims.
3. Remedies
Medicis sought injunctive relief and damages. The jury awarded monetary damages, including lost profits and reasonable royalties. The court granted injunctive relief prohibiting Nycomed from manufacturing or selling infringing products.
Patent Disputes and Outcomes
| Issue |
Details |
Outcome |
| Validity |
Challenged on anticipation and obviousness |
Upheld |
| Infringement |
Products matched patent claims |
Found infringing |
| Damages |
Including lost profits |
Awarded |
Impact and Industry Significance
The case clarified patent scope for dermatological formulations, influencing subsequent patent enforcement strategies. It reinforced the enforcement of formulation patents in the pharmaceutical industry, particularly for topical dermatological products.
Conclusion
The litigation resulted in a finding of infringement and upheld the patent’s validity, with substantial damages awarded. Nycomed’s appeal did not overturn the core infringement ruling, maintaining Medicis’s patent rights.
Key Takeaways
- Medicis’s patent claims for dermatological formulations have been upheld in court.
- Nycomed’s products were found to infringe under court-accepted claim interpretations.
- The case underscores the importance of claim construction in patent litigation.
- Validity challenges based on anticipation and obviousness can be unsuccessful if sufficient evidence of patent novelty exists.
- Patent enforcement in dermatology remains active, emphasizing formulation-specific patents.
FAQs
Q1: What was the primary legal basis for Nycomed’s challenge?
A1: Nycomed challenged the patent on grounds of anticipation and obviousness under 35 U.S.C. §§ 102 and 103.
Q2: How did the court interpret the patent claims?
A2: The court’s Markman ruling clarified claim scope, emphasizing specific formulation components and their combinations.
Q3: What damages were awarded to Medicis?
A3: The jury awarded damages including lost profits and royalties, with the court enjoining Nycomed from infringing products.
Q4: Did the Federal Circuit affirm the infringement decision?
A4: Yes, the Federal Circuit affirmed the infringement but remanded some claim construction issues.
Q5: How does this case influence dermatology patent strategies?
A5: It highlights the importance of detailed claim drafting and the potential for formulation patents to serve as effective enforcement tools.
Sources
[1] U.S. District Court for the District of Arizona (2010). Medicis Pharmaceutical Corporation v. Nycomed US Inc., Case No. 1:10-cv-00419.
[2] Federal Circuit Court of Appeals (2014). Medicis Pharmaceutical Corp. v. Nycomed US Inc..
[3] United States Patent and Trademark Office. Patent No. 7,785,128.
